Mirum Pharmaceuticals, Inc. has disclosed significant stock transactions by its Chief Executive Officer, Christopher Peetz, in a recent SEC filing. The transactions, reported on November 4, 2026, involve both the acquisition and disposition of shares, which could influence investor sentiment and raise questions about corporate governance practices within the pharmaceutical industry.

Background

Mirum Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, classified under SIC 2834. The company is publicly traded on the Nasdaq under the ticker symbol MIRM. As a large accelerated filer, Mirum is subject to rigorous reporting requirements and must maintain transparency regarding its financial activities and executive transactions.

What the Filing Says

The SEC filing reveals that Peetz acquired 20,000 shares of common stock at a price of $2.936 per share and disposed of 20,000 shares at a significantly higher price of $90 per share on the same day. Following these transactions, Peetz retains a total of 206,637 shares of common stock.

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026."

Additionally, Peetz exercised 20,000 employee stock options at the same price of $2.936, which are fully vested and set to expire on March 11, 2029.

Impact

The transactions may affect various stakeholders, including investors and analysts who monitor executive actions closely. The substantial price difference between the acquisition and disposition of shares could prompt questions about the timing and rationale behind these moves, especially in the context of the company's overall performance and market conditions.

What's Next

The filing does not say what happens next.